NYSE:ALife Sciences
Agilent Technologies (A): Evaluating Valuation After Earnings Beat and FDA Approval Boost
If you’ve been watching Agilent Technologies (A), you might be asking yourself what’s fueling the latest rise in the share price. The company’s Q3 numbers came in ahead of forecasts for both revenue and adjusted earnings, which added some cheer to investors hungry for signs of outperformance. Shortly after earnings, Agilent also received FDA approval for its MMR IHC Panel pharmDx (Dako Omnis) as a companion diagnostic in colorectal cancer. This development could boost its standing in the...